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ABSTRACT
Introduction: Natalizumab (NTZ)
discontinuation can be followed by multiple
sclerosis (MS) disease reactivation. Currently no
disease-modifying drug (DMD) has been shown
to be able to abolish disease reactivation. The
aims of the current study were: (1) to determine
the frequency of MS reactivation after NTZ
discontinuation; (2) to evaluate predictors of
reactivation risk, and (3) to compare the effect
of different treatments in reducing this risk.
Methods: Data from 132 patients with MS
followed-up for 2 years before NTZ treatment
and 1 year after interruption were collected
from two Italian MS centers and
retrospectively evaluated.
Results: Overall, 72 of 132 patients (54.5%) had
relapses after NTZ discontinuation and 60 of
125 patients (48%), who had magnetic
resonance imaging, had radiological
reactivation. Rebound was observed in 28 of
132 patients (21.2%). A higher number of
relapses in the 2 years before NTZ treatment, a
longer washout period, and a lower number
NTZ infusions correlated with reactivation and
rebound. Untreated patients (n = 37) had
higher clinical and radiological activity and
rebound in comparison to patients receiving
DMDs. Moreover, a lower risk of relapses was
found in patients treated with second-line
therapies (NTZ and fingolimod) than in those
treated with first-line therapies (interferon beta,
glatiramer acetate, teriflunomide, azathioprine).
Interestingly, no disease reactivation in off-label
treatment (rituximab, autologous
hematopoietic stem cell transplantation) was
observed.
Conclusion: NTZ discontinuation is a risk for
MS reactivation and rebound. An alternative
treatment should be promptly resumed mainly
in patients with a previous very active disease
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course and with a shorter NTZ therapy.
Second-line therapies demonstrate superiority
in preventing relapses after NTZ
discontinuation.
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INTRODUCTION
Natalizumab (NTZ) is an effective therapy for
reducing disease activity in relapsing–remitting
multiple sclerosis (MS) [1, 2]. However, an
important safety issue related to its use is
progressive multifocal leukoencephalopathy
(PML), a demyelinating brain disease triggered
by the John Cunningham virus (JCV) [3–5]. NTZ
therapy is often discontinued due to the risk of
PML; however, this frequently leads to MS
disease reactivation. A consistent return of
underlying pre-treatment disease activity has
been identified by various authors and peaks
4–7 months following NTZ discontinuation
[6–13]. The possibility of a rebound effect,
where the worsening of disease activity is
beyond pre-treatment levels, has also been
described in different reports [14–16]. This
phenomenon is reported in 10 and 30% of
patients in cohort studies; however, a unique
definition has not currently been found [15, 17,
18].
Several studies have tried to identify the best
therapeutic strategy to prevent disease
reactivation/rebound after NTZ suspension;
however, the optimal alternative treatment
regimen has not yet been identified. Disease
control has been incomplete when patients
switched to interferon beta (IFNb) or
glatiramer acetate (GA) [17, 19, 20].
Fingolimod (FTY) may be a reasonable option
because of its efficacy. A few observational
studies show a reduced annualized relapse rate
(ARR) in patients who switched to FTY
compared with those who remain untreated or
switch to IFNb-1a or GA [21–23]. Others studies
have reported severe MS relapses and radiologic
rebound after the initiation of FTY in patients
previously treated with NTZ [24–26]. However,
a recent study showed a lower risk of magnetic
resonance imaging (MRI) and clinical disease
reactivation if FTY therapy is started 8–12 weeks
after NTZ discontinuation [27].
In the current study, the clinical and
radiological data of patients previously treated
with NTZ were collected and analyzed, and then
followed-up for 1 year after interruption. The
aims of this study were: (1) to determine the
frequency of MS reactivation after NTZ
discontinuation; (2) to evaluate predictors of
reactivation risk, and (3) to compare the effect
of different treatments in reducing this risk.
METHODS
Study Design and Participants
This retrospective study was conducted at two
Italian MS referral centers (Orbassano and
Palermo). Data were collected between
February 2007 and January 2015 and
retrospectively evaluated from electronic
databases and clinical records. Radiological
and clinical information of patients with MS
were analyzed in the 2 years before NTZ
treatment and 1 year after NTZ interruption.
Ethical approval was not necessary due to the
retrospective plan of the study, according to
internal ethical board rules.
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Patient Selection for Data Analysis
We included in our analysis patients with
relapsing–remitting MS who received at least 6
infusions of NTZ therapy and with a follow-up
of at least 12 months after NTZ discontinuation.
Patients who did not meet these inclusion
criteria or who developed PML were excluded
from the analysis.
Outcome Measures
Clinical data were collected 2 years before NTZ
treatment, and 3, 6, 9, and 12 months after
interruption. Clinical MS reactivation was
defined as the presence of documented
relapses and/or the progression of Expanded
Disability Status Scale (EDSS) at the end of
follow-up. Radiological MS reactivation was
defined as the appearance of new T2?/FLAIR
lesions and/or Gd-enhancing lesions. As this
was a retrospective study, MRI frequency was
not regularly scheduled and so radiological
evaluation was done where MRI was available.
The literature lacks a clear and univocal
definition of rebound activity. It has been
defined as a fatal relapse, or as any radiological
or disease activity beyond that seen in the
pre-NTZ period. Therefore, an objective
definition based on at least two of the
following features was arbitrarily decided:
1. An ARR increase in comparison to pre-NTZ
disease course;
2. One or more severe relapses with sustained
disability progression (one-step EDSS
increase);
3. Three or more new large T2 lesions and/or
Gd-enhancing lesions in the MRI;
4. New tumor-like demyelinating lesions in
the MRI.
Statistical Analysis
All statistical analyses were performed using
SPSS Statistics version 17.0 (SPSS Inc., Chicago,
IL, USA). The correlation between different
variables and MS reactivation was analyzed
using a univariate statistical analysis: t test for
continuous variables and v2 test for categorical
variables. A Cox multivariate regression model
was used to minimize the bias effect of
unadjusted variables due to the nature of this
retrospective analysis. Data were adjusted for
number of infusions, relapses in the 2 years
before NTZ, washout period between NTZ and
new therapy, and therapeutic strategies after
NTZ (no therapy, first-line therapies, FTY, NTZ).
Statistical significance was defined by a P value
\0.05. Groups with few patients (B8 patients)
were excluded from the analysis (rituximab,
immunosuppressive therapy, autologous
hematopoietic stem cell transplant [AHSCT]).
RESULTS
Demographic and Baseline Characteristics
Of the 346 patients treated with NTZ at the two
referral centers, 192 had discontinued
treatment: 67 patients from the Palermo MS
centre and 125 patients from the Orbassano MS
centre. Data from the Orbassano population
have been previously described [28]. In
particular, the number of patients was lower
and with a follow-up ranging between 1 and
12 months after NTZ discontinuation.
Subsequently, 57 patients who did not meet
the inclusion criteria and three patients who
unfortunately developed PML were excluded
from the analysis. A total of 132 patents were
included in the study (Fig. 1).
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Of the 132 patients included, 56 were male
and 76 were female. The median age at NTZ
initiation was 35.4 years (range 29.8–42 years)
and the median EDSS score was 3.5. The median
EDSS score 12 months after NTZ
discontinuation was 4.0. The median washout
time out was 5 months (range 0.3–11 months).
No differences between male and female
patients were reported. The primary reason for
NTZ interruption was connected to the risk of
PML (Table 1).
Disease Reactivation
Disease reactivation occurred in many patients:
72 of 132 patients (54.5%) experienced a
clinical reactivation. In our analysis 125 of 132
patients performed at least one MRI
examination after NTZ discontinuation: 60 out
of 125 (48%) presented a radiological
reactivation. Furthermore, 28 of 132 patients
(21.2%) had rebound. Clinical and radiological
disease activity was most frequent between 6
and 9 months following NTZ discontinuation.
A peak in clinical reactivation was found in
7 months after NTZ discontinuation; the
frequency of disease reactivation gradually
decreased until the end of the follow-up.
Similarly, a peak in rebound activity was
observed at 7 months, whereas the greater
radiological activity was detected at 9 months
after NTZ discontinuation.
Effect of Different Treatments
Ninety-five patients (72%) were switched to
other therapies after a median washout period
of 5 months: 57 switched to FTY, 16 to first-line
therapies (IFNb, GA, teriflunomide,
azathioprine), 9 to NTZ, 7 to rituximab, 4 to
immunosuppressive agents (cyclophosphamide
or mitoxantrone), and 2 to AHSCT.
Thirty-seven patients (28%) remained therapy
free.
More clinical and radiological reactivation
was observed in the therapy-free and first-line
therapy groups. One patient treated with
mitoxantrone developed a rebound with a
strong clinical and radiological reactivation;
this was a patient with very aggressive disease,
even before and during NTZ treatment. Among
patients who switched to FTY, clinical
reactivation was observed in 10 patients
(17.5%) and radiological reactivation was
observed in 13 patients (23.6%). Clinical
reactivation and rebound effect was not seen
in patients who restarted NTZ; only one patient
out of nine who restarted NTZ therapy
presented radiological reactivation.
192
Paents who have stopped NTZ from February
2007 to January 2015  
132
Paents enrolled in the study
26
<6 NTZ infusions
31
follow-up <12 months
3
paents developed PML
Fig. 1 Enrolment of patients in the study. NTZ natal-
izumab, PML progressive multifocal leukoencephalopathy
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Interestingly, no evidence of disease
reactivation was observed in the rituximab and
AHSCT groups.
Table 2 describes the frequency of disease
reactivation according to the different
treatment strategies. Table 3 reports the
univariate analysis of the different treatments
used; for this analysis only groups with a
consistent number of patients were included.
Interestingly, disease reactivation in the
first-line therapy group was not different than
in the therapy-free group.
Worsening disability was observed in
patients who were therapy free compared to
those who restarted DMDs. In fact, at 1 year of
follow-up the median EDSS increased from 4.0
(EDSS score at NTZ initiation) to 5.5 (EDSS score
12 months after NTZ discontinuation) in the
therapy-free group. A median increase of less
than one point EDSS was seen in the treated
groups.
Predictors of Reactivation Risk
Predictors of disease reactivation were the
number of NTZ infusions and the duration of
the washout period. In particular, a long
washout period correlated with MS
reactivation at 3 (v2 8.1, degrees of freedom
[DF] 2, P = 0.03), 9 (v2 8.1, DF 2, P = 0.03), and
12 months (v2 9.7, DF 2, P = 0.01) after NTZ
discontinuation. A lower number of infusions
correlated with disease reactivation at
12 months (v210.06, DF 2, P = 0.01) and
rebound at 6 (v2 7.5, DF 2, P = 0.04) and
12 months (v2 8.7, DF 2, P = 0.02) after NTZ
interruption. In addition, a correlation between
a higher number of relapses in the 2 years before
NTZ treatment and clinical reactivation at
12 months after NTZ discontinuation was
observed (v2 81, DF 5, P = 0.01). This
association was also observed for the rebound
at 12 months (v2 11.4, DF 5, P = 0.004). The
univariate statistical model did not stratify
according to the different therapeutic
strategies used. With a multivariate model, no
significant differences were observed.
Nevertheless, the best predictor of disease
reactivation was the number of relapses in the
Table 1 Demographic and baseline characteristics
Characteristics N Median
(Q1–Q3)*
Gender (male/female) 132 56/76
Age (years) 132 41 (34.7–47.4)
Age at onset of NTZ (years) 132 35.4 (29.8–42)
ARR 2 years before NTZ 129 1.0 (1.0–1.5)
EDSS score
NTZ initiation 130 3.5 (2.0–5.5)
3 months after NTZ
discontinuation
132 4.0 (2.0–6.0)
6 months after NTZ
discontinuation
132 4.0 (2.0–6.0)
9 months after NTZ
discontinuation
132 4.0 (2.0–6.0)
12 months after NTZ
discontinuation
132 4.0 (2.0–6.0)
NTZ infusions 132 25 (20.5–38.25)
ARR 12 months after NTZ 132 1 (0–1)
Washout time (months) 95 5 (0.3–11)
Primary reason for stopping NTZ (%)
PML risk 99 75
Pregnancy plan 21 16
Inefﬁcacy 7 5.3
Adverse events 4 3
Cancer 1 0.75
ARR annualized relapse rate, EDSS expanded disability
status scale, NTZ natalizumab, PML progressive
multifocal leukoencephalopathy, Q1 ﬁrst quartile, Q3
third quartile
* Unless otherwise stated
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two years preceding the introduction of NTZ
(clinical activity before NTZ, hazard ratio
[HR] = 1.43).
In addition, relapse risk was different
between treatments. A lower risk of relapses
was found in patients treated with NTZ
(HR = 0.29) or FTY (HR = 0.45) than in those
treated with first-line therapies (HR = 1.6).
Therefore, second-line therapies demonstrated
superiority in preventing disease reactivation
after NTZ discontinuation (Table 4 and Fig. 2).
DISCUSSION
NTZ discontinuation is a frequent clinical
practice, mainly as part of the PML risk
management strategy. However, NTZ
suspension has been associated with a
significant disease return often presenting with
severe clinical and radiological manifestations.
This retrospective study of clinical practice
observed patients with MS after NTZ
discontinuation to determine the frequency of
disease reactivation and to compare the effect of
different treatments in reducing this risk.
Our results showed that disease reactivation
occurred in more than half of patients who
discontinue NTZ and it is most frequent in the
6–9 months following the last infusion of NTZ.
It is known from the literature that the
concentration of NTZ progressively decreases
within 3 months, and changes induced on the
immune system can be detected until 6 months
after discontinuation [29]. Accordingly, we
found a peak of clinical reactivation in
month 6 after discontinuation and this
activity decreased gradually until 1 year of
follow-up. Similarly, we observed greater
radiological activity in months 6–9, with a
peak at month 9 after NTZ discontinuation.
Our study confirms literature data, since the
majority of our patients showed a substantial
return to their pre-NTZ disease activity [6–8].
However, we found that 30% of patients
developed a rebound activity, and this
phenomenon is more frequent if compared
Table 2 Clinical/radiological reactivation and rebound in different treatments after NTZ discontinuation
Therapy Total population Clinical reactivation Radiological reactivation Rebound
Therapy-free 28 (37) 59.5 (22) 51.4 (18) 21.6 (8)
NTZ 6.8 (9) 11 (1) 0 (0) 0 (0)
FTY 43.2 (57) 17.5 (10) 23.6 (13) 7 (4)
First-line therapies 12.1 (16) 68.7 (11) 28.6 (4) 12.5 (2)
Immunosuppressive treatment 3 (4) 25 (1) 33.3 (1) 25 (1)
Rituximab 5.3 (7) 0 (0) 0 (0) 0 (0)
AHSCT 1.5 (2) 0 (0) 0 (0) 0 (0)
Values are presented as percentage (N). More clinical and radiological reactivation was observed in therapy-free group and
ﬁrst-line therapy group. One patient treated with immunosuppressive therapy (mitoxantrone) has developed rebound with a
strong clinical and radiological reactivation. Only one patient out of nine who restarted NTZ therapy presented a
radiological reactivation. Ten patients (17.5%) who switched to FTY showed a clinical reactivation and 13 patients (23.6%)
showed a radiological reactivation. No evidence of disease reactivation was observed in rituximab and AHSCT groups
AHSCT autologous hematopoietic stem cell transplant, FTY ﬁngolimod, NTZ natalizumab
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with literature data, probably due to our
operative definition as a communal definition
has not yet been established [15].
Some studies have identified predictive
variables of disease activity for patients
discontinuing NTZ: A higher pre-NTZ disease
activity and long washout period are factors
predicting reactivation [6, 27]. Also in our
analysis we confirmed that a higher number of
relapses in the 2 years before NTZ treatment and
a long washout period were correlated to MS
reactivation and rebound. These data indicate
that an alternative treatment should be
promptly resumed mainly in patients with
high disease activity the year before initiating
NTZ. In addition, we observed also a correlation
between a lower number of infusions of NTZ
and clinical reactivation and rebound. The
association with short-term use of NTZ has
been suggested by few authors, but has not
been proven [14, 16].
The second aim of our analysis was to
evaluate the effects of different therapeutic
strategies to reduce disease activity after NTZ
interruption. We have observed that
second-line therapies were greater for
Table 3 Univariate analysis of different treatments used
Treatment Clinical reactivation (%) Statistical test
v2 DF P value
Therapy-free 59.5
First-line therapy 68.7 1.8 1 0.2
FTY 17.5 37.7 1 \0.0001
NTZ 11 51.5 1 \0.0001
Treatment Radiological
reactivation (%)
Statistical test
v2 DF P value
Therapy-free 51.4
First-line therapy 28.6 10.8 1 0.002
FTY 23.6 165 1 0.0001
NTZ 0 – – –
Treatment Rebound (%) Statistical test
v2 DF P value
Therapy-free 21.6
First-line therapy 12.5 2.9 1 0.13
FTY 7 8.7 1 0.006
NTZ 0 – – –
In the univariate analysis, we have excluded groups with few patients (rituximab, immunosuppressive therapy, AHSCT).
The other therapeutic groups (ﬁrst-line therapy, FTY, NTZ) have been compared to the therapy-free group. Analysis
showed an association between second-line therapy (FTY and NTZ) and a lower clinical and radiological reactivation, and
rebound
AHSCT autologous hematopoietic stem cell transplant, DF degrees of freedom, FTY ﬁngolimod, NTZ natalizumab
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preventing disease reactivation compared to
none treatment or to first-line therapies. The
ineffectiveness of first-line therapies has been
confirmed in numerous published data and in
clinical experience [17, 19, 23].
In our analysis, nine patients were retreated
with NTZ after its withdrawal. These patients
had discontinued treatment because they had a
positivity to Stratify test (STRATIFY Gen1); but
when STRATIFY Gen2 test showed a low
anti-JCV antibodies index [30], these patients
reconsidered to restart NTZ therapy, also
justified by a recurrence of disease activity.
FTY is a second-line therapy and may be a
therapeutic option, especially if it is started
early after NTZ discontinuation [19, 21, 27, 31].
However, FTY did not abolish disease activity
risk and indeed in our cohort we confirmed a
clinical reactivation in 10 out of 57 patients
(17.5%) and radiological reactivation in 13 out
55 patients (23.6%).
Patients with an aggressive inflammatory
clinical course have been treated with
immunosuppressive agents (cyclophosphamide
or mitoxantrone), AHSCT, and rituximab; no
patients were treated with alemtuzumab as it
was not available at the time of study.
The use of immunosuppressive agents may
be a strategy for patients with aggressive disease,
but no definite indication can be done because
of our sample size (only 4 patients).
Interesting data were detected in a few
patients treated with rituximab (7 patients): no
clinical or radiological activity was observed.
The median washout period between NTZ
suspension and rituximab was 3.8 months
(range 1.5–7.8 months). They were patients
Table 4 Multivariate analysis
Variable HR 95% CI P value
Clinical activity before NTZ 1.43 0.7–2.9 0.31
Infusions NTZ 0.99 0.9–1.0 0.66
Washout period 1.0 0.9–1.0 0.618
DMDs 0.019
First-line therapies vs.
therapy-free
1.6 0.4–5.3 0.43
FTY vs. therapy-free 0.45 0.1–1.2 0.13
NTZ vs. therapy-free 0.29 0.03–2.3 0.24
The relapse risk was estimated through a Cox regression
model adjusted for: number of infusions, relapses in the
2 years before NTZ, washout period between NTZ and
new therapy, therapeutic strategies after NTZ (no therapy,
ﬁrst-line therapies, FTY, NTZ); we have excluded groups
with few patients (rituximab, immunosuppressive therapy,
AHSCT). Value of HR is different between ﬁrst-line
therapy and second-line therapies
AHSCT autologous hematopoietic stem cell transplant, CI
conﬁdence interval, DMDs disease-modifying drugs, FTY
ﬁngolimod, HR hazard ratio, NTZ natalizumab
Fig. 2 The relapse risk estimated between therapeutic
strategies at 12 months after NTZ discontinuation. Green
line ﬁrst-line therapy group. Blue line therapy-free group.
Purple line NTZ group. Yellow line FTY group. The HR
values for the groups were as follows: ﬁrst-line ther-
apy = 1.6; NTZ = 0.29; FTY = 0.45. The HR value of
ﬁrst-line therapy group was similar to HR value of
therapy-free group. The relapse risk was lower in patients
treated with NTZ or FTY. FTY ﬁngolimod, HR hazard
ratio, NTZ natalizumab
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with an active disease but had refused AHSCT
and had disagreed to the use of
cyclophosphamide as they were young women
and wanted to plan a future pregnancy. We
choose rituximab treatment because literature
data suggest rituximab is effective in patients
with aggressive relapsing–remitting MS;
however, its use is off-label. We are aware that
a larger sample size and longer follow-up are
needed to confirm this preliminary result [32].
We do not know the PML risk in patients
treated with rituximab after NTZ
discontinuation. PML risk restricted to
rituximab is difficult to establish; in literature,
PML during rituximab therapy was described in
patients treated previously with a broad
spectrum of immunosuppressive agents
[33–35].
In our analysis, patients treated with
rituximab were from the MS center of
Orbassano. All of these patients underwent
MRI examination at NTZ discontinuation and
just before the first infusion of rituximab in
order to exclude the risk of a clinical
undetectable PML.
Two patients were switched to AHSCT; one
patient switched to AHSCT 4.5 months after
NTZ discontinuation, the other patient
switched after 5.6 months. They had very
aggressive disease with high radiological and
clinical activity before NTZ treatment and after
suspension; in particular, one patient
experienced one clinical and radiological
reactivation in the first month after NTZ
discontinuation, the other patient in the third
month after suspension. The choice of this
therapy strategy was due to evidence of
efficacy in patients with very aggressive
relapsing–remitting MS [36, 37].
Limitations of our investigation include the
low number of patients, the retrospective
design, and the lack of complete radiological
data. To verify our retrospective results, a
prospective and randomized study with a
larger sample should be performed;
nevertheless, such a study is unlikely as there
is not an optimal therapeutic strategy after NTZ
discontinuation and therefore therapy of
patients is always personalized. As such,
retrospective studies are the best methodology
today to help neurologists in the management
of treatment in NTZ discontinuation period.
CONCLUSIONS
NTZ interruption represents a current challenge
in the optimization and tailoring of MS
treatment. Our study confirms the risk of MS
reactivation and rebound after NTZ suspension
and indicate that an alternative treatment
should be promptly resumed mainly in
patients with a previous very active disease
course. There are no established guidelines for
the choice of treatment in patients who
discontinue NTZ, but our results suggest the
use of second-line treatment. Following this
strategy it is mandatory to balance the
risk–benefit ratio at the single patient level
with a shared-decision strategy, including all
the aspects of the patient’s life.
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